2014
1322P Biomarkers Associated with Clinical Activity of Pd-L1 Blockade in Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) in a Phase I Study of Mpdl3280A
Soria J, Gettinger S, Gordon M, Heist R, Horn L, Spigel D, Kowanetz M, Mokatrin A, Xiao Y, Sandler A, Felip E. 1322P Biomarkers Associated with Clinical Activity of Pd-L1 Blockade in Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) in a Phase I Study of Mpdl3280A. Annals Of Oncology 2014, 25: iv465. DOI: 10.1093/annonc/mdu349.101.Peer-Reviewed Original ResearchPD-L1 expressionPD-L1 blockadeIHC 2PD-L1Immune cellsNSCLC ptsB7-H4B7-H3PD-L2Tumor cellsIHC 0Clinical activityNon-small cell lung cancer patientsTumor-infiltrating immune cellsCell lung cancer patientsEmployees of GenentechReceptor PD-1Tumor immune microenvironmentLung cancer patientsPD-L1 IHCPD-L1 bindingRoche/GenentechImmune-related genesBristol-Myers SquibbPFS rates
2013
Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK -positive non-small cell lung cancer (NSCLC).
Solomon B, Gettinger S, Riely G, Gadgeel S, Nokihara H, Han J, Hida T, Satouchi M, Baldini E, Siena S, Yamamoto N, Horn L, Tassell V, Polli A, Camidge D. Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK -positive non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 8105-8105. DOI: 10.1200/jco.2013.31.15_suppl.8105.Peer-Reviewed Original ResearchNon-small cell lung cancerMedian PFSPFS ratesSubgroup analysisSuperior efficacyAdvanced ALK-positive non-small cell lung cancerALK-positive non-small cell lung cancerManageable side-effect profilePrior platinum-based regimenStage IIIB/IVCausality adverse eventsMedian treatment durationPlatinum-based regimenSafety of crizotinibIIIB/IVPhase III studySide effect profileCell lung cancerIndependent radiologic reviewPEM patientsPo bidPROFILE 1007Crizotinib treatmentCare chemotherapyData cutoff